Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Controversial Teva chairman bows out as board revamp continues

In January, Teva chairman Dr. Phillip Frost promised some changes to the company's board in response to investor pressure. But it wasn't until Wednesday that he announced his own exit would be among them.

CEO John Johnson jumps ship as Dendreon sinks lower

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

UPDATED: Shaky Dendreon loses its CEO as debt payments loom

Looks like CEO John Johnson won't be around to go down with Dendreon if the ship sinks. Johnson resigned from the board last week and will give up his CEO post in mid-August, the company said Monday.

Merck exec joins Novartis to helm oncology unit

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Bayer drafts Otsuka exec to lead pharma biz to big growth

Bayer's pharma division has a new president with a big task ahead of him. A week after the company announced its current leader, Andreas Fibig, would jump ship, Bayer says it's chosen an Otsuka Pharmaceutical executive to take the post.

Bayer CEO's long goodbye: Dekkers to depart at end of 2016

Marijn Dekkers has set his own expiration date as Bayer CEO. The German conglomerate said Dekkers would leave at the end of 2016, giving him 7 years in the top slot. It's the latest in a series of executive moves at Bayer, whose HealthCare division has been outperforming the rest of the company.

UPDATED: In management reorg, Teva taps Actavis alum to helm new global generics unit

Teva Pharmaceutical Industries CEO Erez Vigodman has been a busy man. So busy, in fact, it seems the company's press releases barely keep up with him. Today's announcement: Vigodman has overhauled Teva's management structure, winnowing out 6 executive jobs and creating two worldwide divisions. And he recruited a pharma-industry vet to take the helm of one of them.

Novartis nabs Merck exec Bruno Strigini to head up oncology business

Novartis wooed one of Merck & Co.'s top executives to take the helm at its oncology unit.

Metabolic disease, cardio expert joins Pfizer's R&D team

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Former CDER official joins Greenleaf Health, biosimilars experience in tow

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...